{"id":"W2105932257","doi":"10.1093/neuonc/nou356","title":"Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study","year":2015,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":235,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"Merck KGaA","keywords":"Medicine; Temozolomide; Internal medicine; Tolerability; Hazard ratio; Clinical endpoint; Oncology; Chemoradiotherapy; Gastroenterology; Progression-free survival; Phases of clinical research; Randomized controlled trial; Chemotherapy; Adverse effect; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006892176,0.0003140203,0.001677564,0.0001714257,0.0001144636,0.00002245209,0.000127004,0.00008402782,0.000002526883],"category_scores_gemma":[0.0007666743,0.0001598005,0.0000601364,0.0002978029,0.0001935413,0.00008430704,0.0000964121,0.0001136413,3.586878e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005074174,"about_ca_system_score_gemma":0.0004592676,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002686605,"about_ca_topic_score_gemma":0.001197007,"domain_scores_codex":[0.9975942,0.000592735,0.000673352,0.0005011758,0.0003546927,0.0002838705],"domain_scores_gemma":[0.9968292,0.001461669,0.0005820289,0.0004093533,0.0005380277,0.0001797694],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9144276,0.04682599,0.02363751,0.00001366019,0.0008252609,0.0003902566,0.003583165,0.00004373759,0.002231866,0.0000492197,0.0002583498,0.007713396],"study_design_scores_gemma":[0.7943734,0.195918,0.001529817,0.00007315174,0.00105713,0.00001882482,0.0003051271,0.0003297034,0.005753894,0.00003974551,0.0004870226,0.0001141705],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9761046,0.00009958728,0.00001014822,0.001458187,0.0001171909,0.02189311,0.0001580655,0.00002283938,0.0001363026],"genre_scores_gemma":[0.9962351,0.00003267466,0.0006165872,0.0001424511,0.00001728277,0.002820866,0.00007834782,0.00003703115,0.00001965508],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.149092,"threshold_uncertainty_score":0.6516476,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03371996017441568,"score_gpt":0.3346704156490075,"score_spread":0.3009504554745918,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}